Search
Revakinagene taroretcel
go.drugbank.com/drugs/DB05344ApprovedInvestigationalRevakinagene taroretcel is an intraocular implant that contains human cells that have been genetically modified to secrete ciliary neurotrophic factor (CNTF). It is an allogeneic encapsulated cell-based gene therapy that contains 200,000...
Eplerenone
go.drugbank.com/drugs/DB00700ApprovedInvestigationalEplerenone, an aldosterone receptor antagonist similar to spironolactone, has been shown to produce sustained increases in plasma renin and serum aldosterone, consistent with inhibition of the negative regulatory feedback of aldosterone ...
Carfilzomib
go.drugbank.com/drugs/DB08889ApprovedInvestigationalCarfilzomib is an injectable antineoplastic agent (IV only). Chemically, it is a modified tetrapeptidyl epoxide and an analog of epoxomicin. It is also a selective proteasome inhibitor. FDA approved carfilzomib in July 2012 for the treat...
Dihydrotachysterol
go.drugbank.com/drugs/DB01070ApprovedWithdrawnA vitamin D that can be regarded as a reduction product of vitamin D2.
Rose bengal
go.drugbank.com/drugs/DB11182ApprovedInvestigationalRose bengal is a pink stain derived as an analogue of fluorescein. Its disodium salt in ophthalmic solutions has been used as a diagnostic agent in suspected damage to conjunctival and corneal cells. It is also used in laboratory setting...
Asciminib
go.drugbank.com/drugs/DB12597ApprovedInvestigationalAsciminib is a tyrosine kinase inhibitor (TKI) used in the treatment of chronic-phase Philadelphia chromosome-positive chronic myeloid leukemia (Ph+ CML). More specifically, it is an inhibitor of the ABL1 kinase activity of the BCR-ABL1 ...
Doconexent
go.drugbank.com/drugs/DB03756ApprovedInvestigationalA mixture of fish oil and primrose oil, doconexent is used as a high-docosahexaenoic acid (DHA) supplement. DHA is a 22 carbon chain with 6 cis double bonds with anti-inflammatory effects. It can be biosythesized from alpha-linolenic aci...
Abemaciclib
go.drugbank.com/drugs/DB12001ApprovedInvestigationalAbemaciclib is an antitumor agent and dual inhibitor of cyclin-dependent kinases 4 (CDK4) and 6 (CDK6) that are involved in the cell cycle and promotion of cancer cell growth in case of unregulated activity. On September 28, 2017, FDA gr...